ImmunoCellular Therapeutics, Ltd. - FORM 10-K - EX-32.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906 - March 21, 2012

Attached files

file filename
10-K - FORM 10-K - ImmunoCellular Therapeutics, Ltd.d283327d10k.htm
EX-10.51 - EXCLUSIVE LICENSE AGREEMENT - ImmunoCellular Therapeutics, Ltd.d283327dex1051.htm
EX-23.1 - CONSENT OF MARCUM LLP. - ImmunoCellular Therapeutics, Ltd.d283327dex231.htm
EX-23.2 - CONSENT OF STONEFIELD JOSEPHSON, INC. - ImmunoCellular Therapeutics, Ltd.d283327dex232.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d283327dex312.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER UNDER SECTION 302 - ImmunoCellular Therapeutics, Ltd.d283327dex311.htm
EX-32.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 906 - ImmunoCellular Therapeutics, Ltd.d283327dex322.htm
EXCEL - IDEA: XBRL DOCUMENT - ImmunoCellular Therapeutics, Ltd.Financial_Report.xls
EX-10.50 - PATENT LICENSE AGREEMENT - ImmunoCellular Therapeutics, Ltd.d283327dex1050.htm

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to his knowledge:

 

  1. The Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2011 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

    By:  

/s/ Manish Singh, Ph.D.

Date: March 21, 2012       Name:   Manish Singh, Ph.D.
      Title:   President and Chief Executive Officer

ImmunoCellular Therapeutics, Ltd. Reports